Many Factors Influence Selection of CAR T Therapy, Bispecifics in Myeloma
Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.
Source: ajmc.com
Page 2 - Multiple Myeloma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multiple Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multiple Myeloma Program Today - Breaking & Trending Today
Novel Targets Could Expand CAR T-Cell Therapy and Bispecific Antibody Options in Myeloma
Ajai Chari, MD, discusses selecting between CAR T-cell therapies and bispecific antibodies in multiple myeloma, expands on the factors that can help inform these decisions, and highlights the need for additional data to help inform sequencing and potential combinations for these therapies.
Source: onclive.com
Dr Chari on Currently Available Bispecific Antibodies in Multiple Myeloma
Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.
Source: onclive.com
Dr Chari on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma
Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.
Source: onclive.com
Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple Myeloma
Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.
Source: onclive.com